(NASDAQ: LYEL) Lyell Immunopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.66%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.69%.
Lyell Immunopharma's earnings in 2026 is -$255,160,000.On average, 11 Wall Street analysts forecast LYEL's earnings for 2026 to be -$181,977,435, with the lowest LYEL earnings forecast at -$184,317,981, and the highest LYEL earnings forecast at -$172,185,004. On average, 11 Wall Street analysts forecast LYEL's earnings for 2027 to be -$191,730,529, with the lowest LYEL earnings forecast at -$235,156,012, and the highest LYEL earnings forecast at -$135,011,630.
In 2028, LYEL is forecast to generate -$156,583,005 in earnings, with the lowest earnings forecast at -$173,957,624 and the highest earnings forecast at -$131,655,701.